Covered recipient · General Payments record
JOSE R GONZALEZ CHAVEZ
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$70,903.06
183 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $61,471.68 | 25 |
| Food and Beverage | $4,628.15 | 152 |
| Consulting Fee | $2,610.00 | 2 |
| Travel and Lodging | $2,193.23 | 4 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $34,099.69 | 36 |
| E.R. Squibb & Sons, L.L.C. | $8,848.11 | 14 |
| ABBVIE INC. | $7,911.82 | 30 |
| Amgen Inc. | $7,351.99 | 10 |
| Lilly USA, LLC | $7,318.71 | 5 |
| Eli Lilly and Company | $3,450.00 | 2 |
| Janssen Pharmaceuticals, Inc | $533.68 | 24 |
| Novartis Pharmaceuticals Corporation | $469.35 | 25 |
| LEO Pharma Inc. | $380.94 | 17 |
| Eli Lilly Export S.A. Puerto Rico Branch | $221.46 | 10 |
| UCB, Inc. | $161.06 | 2 |
| PBG PUERTO RICO LLC | $91.73 | 4 |
| Organon LLC | $64.52 | 4 |
Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOSE R GONZALEZ CHAVEZ
NPI 1619930682 · CMS profile ID 254581
Allopathic & Osteopathic Physicians / Dermatology
SAN JUAN, PR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1619930682?year=2022&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOSE R GONZALEZ CHAVEZ, NPI 1619930682, CMS profile ID 254581. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619930682?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). JOSE R GONZALEZ CHAVEZ, NPI 1619930682, CMS profile ID 254581. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619930682?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- JOSE R GONZALEZ CHAVEZ, NPI 1619930682, CMS profile ID 254581, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1619930682?year=2022&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
183 matching records · $70,903.06 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–183 of 183.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $22.36 | 03/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886869169 | CMS |
| Novartis Pharmaceuticals Corporation | $18.94 | 03/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893708841 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918107157 | CMS |
| PBG PUERTO RICO LLC | $23.89 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949630991 | CMS |
| Novartis Pharmaceuticals Corporation | $16.98 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893708839 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.65 | 03/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932897741 | CMS |
| Organon LLC | $20.00 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946431205 | CMS |
| Janssen Pharmaceuticals, Inc | $7.20 | 02/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886869173 | CMS |
| Novartis Pharmaceuticals Corporation | $23.75 | 02/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893708837 | CMS |
| ABBVIE INC. | $25.55 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892667539 | CMS |
| GENZYME CORPORATION | $124.19 | 02/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938809257 | CMS |
| GENZYME CORPORATION | $4,383.60 | 02/23/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938809259 | CMS |
| GENZYME CORPORATION | $793.10 | 02/23/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938809261 | CMS |
| GENZYME CORPORATION | $25.00 | 02/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938809187 | CMS |
| UCB, Inc. | $28.57 | 02/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908005455 | CMS |
| UCB, Inc. | $132.49 | 02/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908005457 | CMS |
| LEO Pharma Inc. | $27.71 | 02/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 936222183 | CMS |
| Janssen Pharmaceuticals, Inc | $28.85 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886869149 | CMS |
| GENZYME CORPORATION | $25.00 | 02/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938809191 | CMS |
| Novartis Pharmaceuticals Corporation | $18.94 | 02/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893708835 | CMS |
| Amgen Inc. | $1,200.00 | 02/11/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939951187 | CMS |
| E.R. Squibb & Sons, L.L.C. | $7.84 | 02/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932897733 | CMS |
| Novartis Pharmaceuticals Corporation | $20.73 | 02/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893708833 | CMS |
| ABBVIE INC. | $2.41 | 01/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892667537 | CMS |
| GENZYME CORPORATION | $4.15 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938809175 | CMS |
| LEO Pharma Inc. | $24.52 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 936222179 | CMS |
| Novartis Pharmaceuticals Corporation | $21.36 | 01/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893708829 | CMS |
| ABBVIE INC. | $24.30 | 01/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892667535 | CMS |
| Janssen Pharmaceuticals, Inc | $6.29 | 01/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886869181 | CMS |
| Novartis Pharmaceuticals Corporation | $17.65 | 01/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893708831 | CMS |
| Janssen Pharmaceuticals, Inc | $25.57 | 01/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886869175 | CMS |
| LEO Pharma Inc. | $30.79 | 01/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 936222175 | CMS |
| Novartis Pharmaceuticals Corporation | $14.21 | 01/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893708827 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $715,894.02 | 101 |
| PY2024 | Recipient | $104.58 | 1 |
| PY2024 | Principal investigator | $557,835.53 | 79 |
| PY2023 | Principal investigator | $211,603.39 | 73 |
| PY2022 | Recipient | $1,665.00 | 2 |
| PY2022 | Principal investigator | $188,895.32 | 75 |
| PY2021 | Recipient | $17,558.77 | 3 |
| PY2021 | Principal investigator | $754,611.65 | 68 |
| PY2020 | Recipient | $2,933.25 | 3 |
| PY2020 | Principal investigator | $668,450.18 | 52 |
| PY2019 | Recipient | $37,426.34 | 13 |
| PY2019 | Principal investigator | $1,349,911.43 | 32 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
101 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity SAN JUAN MED | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202534797 |
| Principal investigator 1 | UCB SA | $2,853.80 | 12/26/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246656876 |
| Principal investigator 1 | UCB SA | $1,891.45 | 12/26/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246656880 |
| Principal investigator 1 | ABBVIE INC. | $2,125.00 | 12/18/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202531140 |
| Principal investigator 1 | ABBVIE INC. | $425.00 | 12/18/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202531142 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 12/18/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202531144 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 12/11/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202530004 |
| Principal investigator 1 | ABBVIE INC. | $6,529.46 | 12/04/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202526926 |
| Principal investigator 1 | ABBVIE INC. | $3,998.38 | 12/04/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202527018 |
| Principal investigator 1 | ABBVIE INC. | $64,199.16 | 11/26/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202525500 |
| Principal investigator 1 | UCB SA | $90.00 | 11/24/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658838 |
| Principal investigator 1 | UCB SA | $2,000.00 | 11/24/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658868 |
| Principal investigator 1 | UCB SA | $500.00 | 11/24/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658870 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 11/06/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202523309 |
| Principal investigator 1 | ABBVIE INC. | $125.00 | 11/06/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202523445 |
| Principal investigator 1 | ABBVIE INC. | $1,025.00 | 11/06/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202523447 |
| Principal investigator 1 | ABBVIE INC. | $3,305.58 | 11/05/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202521987 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 11/05/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202521989 |
| Principal investigator 1 | ABBVIE INC. | $18,949.86 | 11/05/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202522059 |
| Principal investigator 1 | ABBVIE INC. | $2,147.24 | 11/04/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202520451 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 10/28/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202518833 |
| Principal investigator 1 | ABBVIE INC. | $1,150.00 | 10/17/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202517429 |
| Principal investigator 1 | ABBVIE INC. | $1,572.50 | 10/09/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202515477 |
| Principal investigator 1 | ABBVIE INC. | $4,246.18 | 10/09/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202515479 |
| Principal investigator 1 | ABBVIE INC. | $5,450.00 | 10/09/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202515497 |
| Principal investigator 1 | ABBVIE INC. | $5,239.16 | 10/09/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202516179 |
| Principal investigator 1 | UCB SA | $1,891.45 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658050 |
| Principal investigator 1 | UCB SA | $2,853.80 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658052 |
| Principal investigator 1 | UCB SA | $2,378.80 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658054 |
| Principal investigator 1 | UCB SA | $1,964.00 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658056 |
| Principal investigator 1 | UCB SA | $198.55 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658058 |
| Principal investigator 1 | UCB SA | $519.65 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658060 |
| Principal investigator 1 | UCB SA | $519.65 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658064 |
| Principal investigator 1 | UCB SA | $23,573.95 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658066 |
| Principal investigator 1 | UCB SA | $519.65 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658068 |
| Principal investigator 1 | UCB SA | $519.65 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658070 |
| Principal investigator 1 | UCB SA | $519.65 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658072 |
| Principal investigator 1 | UCB SA | $1,975.05 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658074 |
| Principal investigator 1 | UCB SA | $2,378.80 | 10/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246658076 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 09/17/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202511254 |
| Principal investigator 1 | ABBVIE INC. | $822.50 | 09/17/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202511256 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 09/16/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202510980 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 09/16/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202510982 |
| Principal investigator 1 | ABBVIE INC. | $172.50 | 09/11/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202510596 |
| Principal investigator 1 | ABBVIE INC. | $10,133.05 | 09/04/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202508448 |
| Principal investigator 1 | ABBVIE INC. | $9,078.68 | 09/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202508292 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 08/14/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202504705 |
| Principal investigator 1 | ABBVIE INC. | $7,000.00 | 08/14/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202504707 |
| Principal investigator 1 | ABBVIE INC. | $25.00 | 08/14/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202504709 |
| Principal investigator 1 | ABBVIE INC. | $8,800.00 | 08/12/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202504237 |
| Principal investigator 1 | ABBVIE INC. | $783.75 | 07/24/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202499562 |
| Principal investigator 1 | ABBVIE INC. | $1,650.00 | 07/14/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202498158 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 07/10/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202497966 |
| Principal investigator 1 | ABBVIE INC. | $375.00 | 07/09/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202497602 |
| Principal investigator 1 | ABBVIE INC. | $2,190.62 | 07/08/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497150 |
| Principal investigator 1 | ABBVIE INC. | $4,836.00 | 07/08/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202497192 |
| Principal investigator 1 | ABBVIE INC. | $157.48 | 07/02/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202494909 |
| Principal investigator 1 | ABBVIE INC. | $3,867.16 | 07/02/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202495013 |
| Principal investigator 1 | ABBVIE INC. | $7,848.47 | 07/02/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202495015 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 06/18/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202492095 |
| Principal investigator 1 | ABBVIE INC. | $172.50 | 06/17/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202491715 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $650.00 | 06/09/2025 | Non-covered Recipient Entity Gcm Medical Group PSC | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226135160 |
| Principal investigator 1 | ABBVIE INC. | $5,209.98 | 06/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202487679 |
| Principal investigator 1 | ABBVIE INC. | $3,796.30 | 06/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202487681 |
| Principal investigator 1 | ABBVIE INC. | $4,836.00 | 06/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202487683 |
| Principal investigator 1 | ABBVIE INC. | $3,998.38 | 06/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202488727 |
| Principal investigator 1 | ABBVIE INC. | $533.75 | 05/14/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202484811 |
| Principal investigator 1 | ABBVIE INC. | $175.00 | 05/08/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202484275 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $25,382.00 | 05/08/2025 | Non-covered Recipient Entity Gcm Medical Group | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235997187 |
| Principal investigator 1 | ABBVIE INC. | $3,305.58 | 05/07/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202482621 |
| Principal investigator 1 | ABBVIE INC. | $9,162.26 | 05/07/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202482731 |
| Principal investigator 1 | ABBVIE INC. | $900.00 | 05/06/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202481251 |
| Principal investigator 1 | ABBVIE INC. | $4,995.48 | 05/06/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202481365 |
| Principal investigator 1 | ABBVIE INC. | $4,800.00 | 04/15/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202476501 |
| Principal investigator 1 | ABBVIE INC. | $33.75 | 04/10/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202475781 |
| Principal investigator 1 | ABBVIE INC. | $21,385.00 | 04/09/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202475091 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $20,500.00 | 04/07/2025 | Non-covered Recipient Entity Gcm Medical Group PSC | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226135114 |
| Principal investigator 1 | ABBVIE INC. | $4,395.78 | 04/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202469727 |
| Principal investigator 1 | ABBVIE INC. | $3,706.64 | 04/03/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202471615 |
| Principal investigator 1 | Amgen Inc. | $31,311.80 | 03/25/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246641729 |
| Principal investigator 1 | ABBVIE INC. | $2,935.28 | 03/13/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202463637 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 03/13/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202463730 |
| Principal investigator 1 | Eli Lilly and Company | $1,230.27 | 03/10/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187883458 |
| Principal investigator 1 | ABBVIE INC. | $4,775.38 | 03/07/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202461768 |
| Principal investigator 1 | ABBVIE INC. | $10,038.18 | 03/07/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202462094 |
| Principal investigator 1 | ABBVIE INC. | $664.00 | 02/24/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202453624 |
| Principal investigator 1 | ABBVIE INC. | $2,615.58 | 02/20/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202452899 |
| Principal investigator 1 | ABBVIE INC. | $4,800.00 | 02/13/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202451181 |
| Principal investigator 1 | ABBVIE INC. | $260.00 | 02/12/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202450824 |
| Principal investigator 1 | ABBVIE INC. | $135.00 | 02/12/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202450829 |
| Principal investigator 1 | ABBVIE INC. | $19,546.71 | 02/06/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202447749 |
| Principal investigator 1 | ABBVIE INC. | $19,568.87 | 02/06/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202447887 |
| Principal investigator 1 | ABBVIE INC. | $18,500.00 | 02/06/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202447898 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $91,957.00 | 01/30/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187881868 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $55.02 | 01/27/2025 | Non-covered Recipient Entity Gcm Medical Group | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235997189 |
| Principal investigator 1 | Eli Lilly and Company | $3,929.30 | 01/27/2025 | Covered Recipient Teaching Hospital DRISCOLL CHILDRENS HOSPITAL | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187872407 |
| Principal investigator 1 | Amgen Inc. | $46,871.15 | 01/22/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246641732 |
| Principal investigator 1 | ABBVIE INC. | $953.80 | 01/20/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202440067 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $91,568.00 | 01/16/2025 | Non-covered Recipient Entity Gcm Medical Group Psc | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235997185 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $12,750.00 | 01/16/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187882802 |
| Principal investigator 1 | ABBVIE INC. | $241.50 | 01/14/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202438314 |